Key facts
- It has raised $14.1M; the latest was Early Stage VC ($14.1M) in Nov 2025.
- Notable investors include Shenzhen Capital Group, Wuxi Capital, BGI Co-Win, Bangming Capital, Shanghai Xiangrong Investment — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Waker Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Waker Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Waker Bioscience
Provider of gene therapy safety evaluation services designed for clinical and regulatory risk assessment purposes. The company is mainly focused on the research and development of high-precision crispr/cas 9 quantitative off-target analysis, vector copy number (VCN), vector quality control, immune repertoire analysis, and efficient sgRNA screening, providing clients with a full range of customized services from receiving samples to report submission.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- wakerbio.com/
- Ownership
- Privately Held (backing)
Waker Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Waker Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Waker Bioscience in its N-PORT filings yet. We sweep new filings monthly.